Zacks: Analysts Anticipate Balchem Co. (NASDAQ:BCPC) Will Post Quarterly Sales of $172.25 Million

Analysts expect Balchem Co. (NASDAQ:BCPC) to announce sales of $172.25 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Balchem’s earnings, with the highest sales estimate coming in at $179.00 million and the lowest estimate coming in at $165.50 million. Balchem posted sales of $163.54 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 5.3%. The company is expected to announce its next earnings results on Thursday, February 27th.

According to Zacks, analysts expect that Balchem will report full year sales of $649.45 million for the current fiscal year, with estimates ranging from $642.70 million to $656.20 million. For the next fiscal year, analysts expect that the company will post sales of $757.35 million, with estimates ranging from $678.70 million to $836.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Balchem.

Balchem (NASDAQ:BCPC) last posted its quarterly earnings data on Tuesday, November 5th. The basic materials company reported $0.81 EPS for the quarter, beating the consensus estimate of $0.74 by $0.07. The business had revenue of $158.60 million for the quarter, compared to analysts’ expectations of $166.42 million. Balchem had a net margin of 12.43% and a return on equity of 14.01%. The firm’s revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 EPS.

Several equities research analysts recently commented on the stock. Zacks Investment Research cut shares of Balchem from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 7th. BidaskClub cut shares of Balchem from a “hold” rating to a “sell” rating in a research report on Thursday, November 21st. HC Wainwright reissued a “positive” rating and set a $110.00 price target (up from $95.00) on shares of Balchem in a research report on Wednesday, November 6th. Finally, ValuEngine cut shares of Balchem from a “hold” rating to a “sell” rating in a research report on Wednesday, December 4th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $107.67.

BCPC traded up $2.04 during trading on Friday, hitting $104.00. The company had a trading volume of 84,471 shares, compared to its average volume of 112,779. The company has a market capitalization of $3.25 billion, a PE ratio of 34.55 and a beta of 1.18. Balchem has a one year low of $73.16 and a one year high of $106.56. The firm’s 50-day moving average price is $101.23 and its 200 day moving average price is $97.31. The company has a quick ratio of 2.31, a current ratio of 3.33 and a debt-to-equity ratio of 0.32.

A number of large investors have recently modified their holdings of BCPC. CWM LLC bought a new stake in Balchem during the 2nd quarter worth about $31,000. Krane Funds Advisors LLC bought a new stake in Balchem during the 2nd quarter worth about $60,000. Tower Research Capital LLC TRC bought a new stake in Balchem during the 2nd quarter worth about $65,000. First Mercantile Trust Co. bought a new stake in Balchem during the 3rd quarter worth about $72,000. Finally, HM Payson & Co. bought a new stake in Balchem during the 2nd quarter worth about $147,000. 88.01% of the stock is currently owned by hedge funds and other institutional investors.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.

Featured Story: What are the most popular ETFs

Get a free copy of the Zacks research report on Balchem (BCPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.